| Autor: |
T.V. Chernii, V. I. Chernii, D. A. Fokina |
| Jazyk: |
English<br />Russian<br />Ukrainian |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Клінічна та профілактична медицина, Iss 4, Pp 30-36 (2022) |
| Druh dokumentu: |
article |
| ISSN: |
2616-4868 |
| DOI: |
10.31612/2616-4868.4(22).2022.05 |
| Popis: |
Introduction. Elimination of intracellular energy deficit and "smoldering" systemic inflammation, as well as elimination of water-electrolyte and metabolic disorders can be singled out as the main directions of therapy for the long-term consequences of Long COVID. The aim: to study and analyze the results of treatment with a pathogenetically justified combination of drugs Xavron, Tivorel and Xylat in patients with asthenic manifestations in the framework of Long-COVID. Materials and methods. During 2021, a clinical and neurological examination of 50 patients aged 47 to 76 years with a diagnosis of chronic cerebral ischemia (CMI) and an asthenic syndrome that persisted for more than 3 months after a laboratory-confirmed SARS-CoV-2 infection was carried out. The diagnosis was confirmed by the results of a clinical-neurological and neuropsychological examination using scales for the assessment of cognitive function (MMSE), emotional status (DASS-21), fatigue (FAS) and the neurological deficit assessment scale (MOND) developed by us. 20 patients additionally received a 10-day course of infusions of a combination of Xavron drugs in a dose of 30 mg No. 10, Tivorel 100.0 No. 5, and Xylate 200.0 No. 5 every other day, respectively. Thus, 50 patients were divided into two groups: the first - 20 people and the second - 30 people. Results. Correlation analysis revealed a strong positive correlation between the CIRS-G comorbidity score and the MOND score. A positive correlation coefficient between comorbidity and asthenic syndrome, assessed on the FAS scale, was also expressed - 0.699 (p= |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
